Beijing Bohui Innovation Biotechnology Group Co., Ltd. operates as a high-tech biomedical enterprise, engaging in the research, development, manufacturing, distribution, and comprehensive after-sales support for diagnostic solutions and scientific instrumentation within China and globally. The company's portfolio encompasses advanced in-vitro diagnostic platforms, including fully automated nucleic acid detection systems leveraging microfluidic technology, alongside sophisticated fluorescence immunoassay and trace element analysis instruments. Additionally, it provides a range of analytical instruments such as mass spectrometry platforms and purification systems, enhanced through strategic international acquisitions. Bohui Group further extends its reach into biopharmaceuticals, developing and producing blood products like albumin and immunoglobulins, as well as various vaccine products, with a recent joint venture securing clinical trial approval for an Hib Vaccine. Established in 2001 and headquartered in Beijing, China, the firm was listed on the Shenzhen Stock Exchange ChiNext in May 2012. The company recorded substantial growth, with revenues reaching RMB 1.8 billion in 2023, fueled by strong demand and increased exports.